# Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

> **NCT04978454** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 60 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza RG-A/Texas/71/2017 (H3N2) Challenge
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04978454
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-19
- **Primary completion:** 2022-09-22
- **Final completion:** 2022-09-22
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978454, "Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04978454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*